Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) have been assigned a consensus recommendation of “Buy” from the eight analysts that are currently covering the firm, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $19.00.

A number of equities analysts recently commented on AMRX shares. Barclays raised their price target on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 20th. Wall Street Zen upgraded shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, July 12th. Zacks Research upgraded shares of Amneal Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 7th. UBS Group raised their target price on shares of Amneal Pharmaceuticals from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating and issued a $22.00 price target on shares of Amneal Pharmaceuticals in a research report on Wednesday, August 26th.

Amneal Pharmaceuticals Stock Performance

Shares of NASDAQ AMRX opened at $17.44 on Tuesday. The company has a debt-to-equity ratio of 77.65, a current ratio of 2.20 and a quick ratio of 1.44. The firm has a market cap of $5.57 billion, a price-to-earnings ratio of 35.59 and a beta of 1.24. The stock’s fifty day moving average price is $17.77 and its two-hundred day moving average price is $14.98. Amneal Pharmaceuticals has a one year low of $9.44 and a one year high of $19.26.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its earnings results on Thursday, July 30th. The company reported $0.30 earnings per share for the quarter, topping analysts’ consensus estimates of $0.24 by $0.06. The company had revenue of $796.20 million during the quarter. Amneal Pharmaceuticals had a negative return on equity of 584.46% and a net margin of 5.05%.Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. On average, equities analysts forecast that Amneal Pharmaceuticals will post 0.94 EPS for the current year.

Insiders Place Their Bets

In other news, EVP Jason B. Daly sold 210,000 shares of the company’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $17.40, for a total transaction of $3,654,000.00. Following the completion of the sale, the executive vice president directly owned 35,171 shares in the company, valued at approximately $611,975.40. This represents a 85.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director John Kiely sold 50,000 shares of the stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $17.64, for a total value of $882,000.00. Following the sale, the director directly owned 210,252 shares in the company, valued at approximately $3,708,845.28. This trade represents a 19.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 413,016 shares of company stock worth $7,216,567 in the last 90 days. Company insiders own 17.30% of the company’s stock.

Institutional Investors Weigh In On Amneal Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of AMRX. California State Teachers Retirement System lifted its position in shares of Amneal Pharmaceuticals by 37.6% during the 1st quarter. California State Teachers Retirement System now owns 207,239 shares of the company’s stock worth $2,576,000 after buying an additional 56,588 shares during the last quarter. Louisiana State Employees Retirement System bought a new position in Amneal Pharmaceuticals in the first quarter valued at about $936,000. Renaissance Technologies LLC grew its position in Amneal Pharmaceuticals by 1,586.8% in the first quarter. Renaissance Technologies LLC now owns 276,637 shares of the company’s stock valued at $3,439,000 after acquiring an additional 260,237 shares during the last quarter. HighTower Advisors LLC acquired a new position in Amneal Pharmaceuticals during the fourth quarter worth about $1,121,000. Finally, Arkadios Wealth Advisors acquired a new position in Amneal Pharmaceuticals during the first quarter worth about $4,165,000. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.